Artiva Biotherapeutics (ARTV) COO reports stock award and tax withholding

(Neutral)

Form Type

Rhea-AI Filing Summary

Artiva Biotherapeutics COO and CLO Jennifer Bush reported equity compensation and related tax withholding transactions in company stock. She received a grant of 117,300 shares of common stock as a restricted stock unit award under Artiva’s 2024 Equity Incentive Plan. On the same date, 3,515 shares were withheld by Artiva at a price of $4.00 per share to cover income tax obligations tied to vesting of restricted stock units, rather than sold in the open market. After these transactions, she directly owned 346,710 shares of Artiva common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Bush Jennifer

Role COO, CLO, Secy, Compliance Off

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	117,300	$0.00	--
Tax Withholding	Common Stock	3,515	$4.00	$14K

Holdings After Transaction: Common Stock — 350,225 shares (Direct)

Footnotes (1)

Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/18/2026 - 06:49 PM

FAQ

What did Artiva Biotherapeutics (ARTV) report in Jennifer Bush’s latest Form 4?

Artiva Biotherapeutics reported that executive Jennifer Bush received a 117,300-share restricted stock unit award and had 3,515 shares withheld to cover taxes. These moves reflect routine equity compensation and tax withholding rather than open-market stock purchases or sales.

How many Artiva Biotherapeutics (ARTV) shares did Jennifer Bush acquire in this filing?

Jennifer Bush acquired 117,300 shares of Artiva common stock through a restricted stock unit award. The award was granted under Artiva’s 2024 Equity Incentive Plan and represents stock-based compensation rather than a cash purchase on the open market.

Why were 3,515 Artiva Biotherapeutics (ARTV) shares disposed of in the Form 4?

The 3,515 Artiva shares were withheld by the company at $4.00 per share to satisfy income tax obligations from vesting restricted stock units. This tax-withholding disposition is an administrative step, not a discretionary open-market sale by Jennifer Bush.

What is Jennifer Bush’s Artiva Biotherapeutics (ARTV) ownership after these transactions?

After the reported equity grant and tax withholding, Jennifer Bush directly owned 346,710 shares of Artiva common stock. This total reflects her updated direct holdings following the 117,300-share restricted stock unit award and the 3,515-share tax-withholding disposition.

Was the Artiva Biotherapeutics (ARTV) Form 4 a stock sale by Jennifer Bush?

The Form 4 does not show an open-market stock sale by Jennifer Bush. It records an equity award of 117,300 shares and a 3,515-share tax-withholding disposition, where shares were withheld by Artiva to cover taxes on restricted stock unit vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bush Jennifer

(Last)

(First)

(Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	COO, CLO, Secy, Compliance Off

3. Date of Earliest Transaction (Month/Day/Year)
02/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/15/2026		A		117,300⁽¹⁾	A	$0	350,225	D
Common Stock	02/15/2026		F		3,515⁽²⁾	D	$4	346,710	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

	/s/ Andrew Cronauer, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR